L-glutamic acid is far more than a flavoring agent. It is one of the most abundant amino acids in nature, a central hub of nitrogen metabolism in living cells, and the principal excitatory neurotransmitter in the mammalian nervous system. Industrially, it is produced almost exclusively through microbial fermentation, with the bacterium Corynebacterium glutamicum serving as the dominant workhorse thanks to decades of metabolic engineering. Yet the global appetite for glutamate, driven by its use as a flavor enhancer and its expanding role in food biotechnology, has pushed researchers to look for alternative microbial producers. Lactic acid bacteria are particularly attractive candidates because of their long history of safe use in food, their metabolic versatility, and their regulatory standing as Generally Recognized as Safe in the United States and as holding Qualified Presumption of Safety status in the European Union. The biosynthesis of glutamate in these bacteria is closely tied to the enzyme glutamate dehydrogenase, which catalyzes the amination of alpha-ketoglutarate, and the presence of the gdh gene in many lactic acid bacteria confirms their genetic capacity for the task.

The Brazilian team began with a simple but ambitious question: how many of the lactic acid bacteria in their culture collection could actually make glutamic acid? The 142 isolates, drawn from species including Levilactobacillus brevis, Lacticaseibacillus casei, L. paracasei, Lactiplantibacillus plantarum, and L. fermentum, were grown under microaerobic conditions and tested first by thin-layer chromatography, which revealed that every single isolate produced detectable glutamate. Quantitative screening with a ninhydrin colorimetric assay showed average production of 20.0 millimolar, with values ranging from 10.60 to 33.78 millimolar. Using a selection threshold of 27.19 millimolar, the researchers narrowed the field to 17 high-producing strains, eight of which came from traditional indigenous fermented beverages and nine from other fermented substrates such as fresh pork sausage, cocoa, apple kefir, apple, and pulped coffee.

Precise quantification by high-performance liquid chromatography exposed striking variability among the selected strains, confirming that glutamate production is a highly strain-dependent trait rather than a species-wide characteristic. Extracellular concentrations ranged from 2.42 to 31.97 millimolar, while intracellular accumulation varied from 1.26 to 44.83 millimolar. The two standouts were both L. fermentum strains isolated from Yakupa: CCMA 0209 accumulated the highest intracellular glutamate at 44.83 millimolar, while CCMA 0205 secreted the most extracellular glutamate at 31.97 millimolar. This split between accumulation inside the cell and secretion into the surrounding medium hints that glutamate production and export may be independently regulated processes, a distinction well documented in Corynebacterium glutamicum, where mechanosensitive channels such as MscCG govern glutamate release. Whether similar export mechanisms operate in lactic acid bacteria remains an open question for future research.

With four top producers in hand, the team turned to statistical optimization using a Central Composite Rotational Design, a response surface methodology that evaluates pH, temperature, and incubation time at five coded levels to map how these variables jointly influence production. Only L. fermentum CCMA 0205 yielded a statistically significant predictive model for extracellular glutamate, with a coefficient of determination of 0.83 and a non-significant lack-of-fit test, meaning the fitted equation reliably described the experimental data. Temperature and incubation time emerged as the dominant factors, while pH showed no significant effect within the studied range. Counterintuitively, production was favored at the lower end of the temperature scale and at shorter incubation times, with the highest observed value in the design runs, 4.694 millimolar, obtained at pH 5.5, 30 degrees Celsius, and 48 hours. Higher temperatures and prolonged fermentation reduced yields, possibly through nutrient depletion, accumulation of inhibitory metabolites, or degradation of the amino acid itself.

The researchers are careful to note an important caveat: the 31.97 millimolar figure from the initial screening reflects a seven-day incubation of 168 hours, whereas the optimization design was capped at 112 hours for experimental feasibility. Because the known higher-producing condition lies outside the investigated time domain, the model cannot establish an overall production optimum, and the team recommends that future studies explore longer fermentation times. Numerical optimization within the evaluated design space nevertheless identified a predicted extracellular optimum of 3.86 millimolar at pH 5.5, 30 degrees Celsius, and 48 hours, with a desirability of 0.813. These predictions, the authors stress, require experimental validation before any industrial application.

Intracellular accumulation told a different story. For CCMA 0205, none of the linear effects of pH, temperature, or time reached statistical significance on their own; only the quadratic components mattered, indicating a nonlinear response governed by the combined effects of all three variables. The model explained 84.6 percent of the variability, and numerical optimization pointed to a well-defined maximum of 4.13 millimolar at pH 4.69, 35.3 degrees Celsius, and 72.7 hours. The distinct optima for extracellular and intracellular production suggest that the two processes respond to different physiological signals, reflecting the balance between glutamate biosynthesis, cellular demand, and export. Notably, another strain, L. plantarum SAU 245, reached an intracellular concentration of 10.43 millimolar under specific conditions, but without a significant predictive model its response was too inconsistent to support process development.

Beyond its glutamate output, CCMA 0205 impressed the team with its probiotic-related profile. None of the four selected strains showed hemolytic or DNase activity, two traits commonly associated with bacterial virulence, providing an early safety signal. All strains exhibited high cell surface hydrophobicity exceeding 89 percent, comparable to or higher than values reported for recognized probiotic strains such as Lactobacillus rhamnosus GG and L. plantarum 299v. CCMA 0205 went further, achieving coaggregation rates of 65.71 percent with enteropathogenic Escherichia coli and 65.39 percent with Salmonella enterica serovar Enteritidis, significantly outperforming the other isolates. High hydrophobicity and coaggregation are indirect indicators of an ability to adhere to the intestinal mucosa and to exclude enteric pathogens through competitive interactions, though the authors emphasize that in vitro assays alone do not establish probiotic status and that epithelial adhesion models and in vivo studies will be needed.

Perhaps the most instructive lesson of the study concerns what makes a strain industrially valuable. Several isolates occasionally outperformed CCMA 0205 in individual experimental runs, but the absence of statistically robust predictive models for those strains limits their usefulness, because reproducibility and controllability are paramount in fermentation scale-up. CCMA 0205’s stable, predictable metabolic response, even when its absolute values were not always the highest, is precisely what process engineers need to design rational fermentation strategies. The finding also reinforces a growing appreciation that traditional fermented foods, where microbial communities have adapted to highly competitive ecological niches over generations, are reservoirs of metabolic capabilities that industrial starter cultures often lack.

The convergence of efficient glutamate secretion, predictable fermentation behavior, and favorable surface properties positions L. fermentum CCMA 0205 as a candidate for multifunctional starter cultures that could simultaneously enhance the nutritional, sensory, and functional quality of fermented foods. The research team, supported by Brazil’s National Council for Scientific and Technological Development and the Minas Gerais Research Foundation, plans next to evaluate the strain at pilot scale and to investigate the molecular mechanisms underlying glutamate biosynthesis and secretion in lactic acid bacteria. If those efforts succeed, the umami-enhancing microbe of the future may trace its origins not to an industrial fermenter, but to a centuries-old indigenous beverage from the Brazilian interior.

Subject of Research: L-glutamic acid production and probiotic characterization of lactic acid bacteria isolated from Brazilian fermented foods

Article Title: L-Glutamic acid production by lactic acid bacteria from Brazilian fermented foods: screening, optimization, and probiotic-related properties of Limosilactobacillus fermentum CCMA 0205

Article References: de Lara de Souza, J. G., de Souza, A. C., de Castro, A. T., de Menezes Daloso, D., Schwan, R. F., & Dias, D. R. (2026). L-Glutamic acid production by lactic acid bacteria from Brazilian fermented foods: screening, optimization, and probiotic-related properties of Limosilactobacillus fermentum CCMA 0205. International Microbiology. https://doi.org/10.1007/s10123-026-00905-1

Image Credits: AI Generated

DOI: 10.1007/s10123-026-00905-1

Keywords: L-glutamic acid, lactic acid bacteria, Limosilactobacillus fermentum, Yakupa, fermented foods, umami, probiotics, response surface methodology, fermentation optimization, HPLC, indigenous beverages, food biotechnology

The experimental logic behind the study is rooted in what scientists call the microbiota-gut-brain axis, the bidirectional communication network linking the intestinal microbial community, the gut epithelial barrier, the immune system, and the central nervous system. In recent years, disruptions in this axis have been implicated in a range of neurological conditions, from depression and autism to Parkinson’s and Alzheimer’s disease. In Alzheimer’s specifically, an imbalanced gut microbiota can compromise the intestinal mucosal barrier, allowing bacterial products such as lipopolysaccharides and amyloid-like molecules to circulate, activate microglia, and drive chronic neuroinflammation, which in turn accelerates neurodegeneration.

To model the disease, the researchers injected Wistar albino rats intraperitoneally with aluminium chloride at 50 milligrams per kilogram of body weight and D-galactose at 100 milligrams per kilogram for seven consecutive days. Aluminium is a known neurotoxin that disrupts metal homeostasis and promotes iron-mediated lipid peroxidation, while D-galactose generates reactive oxygen species that damage proteins, lipids, and DNA. Together, the two chemicals reliably produce the pathological signature of Alzheimer’s in rodents: beta-amyloid plaque accumulation, neurofibrillary tangles, declining neurotransmitter levels, and widespread oxidative injury. The team then tested three different probiotic regimens, co-administration alongside the toxins, a prophylactic protocol in which the probiotic preceded the toxins, and a therapeutic protocol in which the probiotic followed the toxin exposure, and compared all of them against a memantine-treated positive control group.

The histopathological results were striking. Congo red staining of brain sections revealed that rats exposed to aluminium chloride and D-galactose developed dense amyloid plaque deposits, cerebral amyloid angiopathy, and neurofibrillary tangles in the hippocampus and cerebral cortex. In the rats that received L. fermentum NCDC701, whether before, during, or after toxin exposure, these abnormalities were markedly reduced, with hippocampal tissue appearing largely normal, cells intact, and no signs of necrosis. Notably, the probiotic-treated groups appeared to outperform memantine, the standard anti-Alzheimer drug used as a positive control, which left some residual plaques and angiopathy. In the colon, haematoxylin and eosin staining showed that the probiotic restored epithelial integrity and reduced the infiltration of inflammatory leukocytes and neutrophils that the toxin regimen had caused.

Biochemical assays using ELISA quantified the molecular shifts underlying these tissue-level changes. The toxin-exposed rats showed elevated concentrations of beta-amyloid peptides 1-40 and 1-42 in both brain and serum, along with depressed levels of the inhibitory neurotransmitter GABA and the monoamine serotonin. Supplementation with L. fermentum NCDC701 reversed both trends, lowering amyloid peptide concentrations and restoring GABA and serotonin toward control levels. This is consistent with the strain’s in vitro profile: the researchers measured GABA production by NCDC701 at approximately 99.43 millimolar, suggesting the bacterium is a substantial neurotransmitter factory. Because GABA decline is considered a contributor to Alzheimer’s symptomatology, and because reduced serotonin has been linked to the aggressive behaviors seen in dementia patients, the neuromodulatory capacity of this strain is of particular interest.

The probiotic also rebalanced the immune chemistry of both brain and colon. Pro-inflammatory cytokines IL-6 and TNF-alpha, which surged after toxin exposure, fell significantly in all three probiotic groups, while the anti-inflammatory cytokine IL-10 rose. At the transcriptional level, RT-qPCR showed that NCDC701 suppressed the expression of p65, a key component of the NF-kappaB inflammatory signaling complex, along with COX-2 and iNOS, two enzymes that amplify inflammatory and oxidative damage, in both brain and colonic tissue. Simultaneously, the strain boosted the activity of the antioxidant enzymes superoxide dismutase, catalase, and glutathione peroxidase, which the toxin regimen had suppressed, thereby restoring the tissue’s capacity to neutralize free radicals.

One of the most clinically relevant findings concerned the gut barrier itself. The mRNA expression of tight junction proteins, zonula occludens-1, occludin, and claudin-1, dropped sharply in the colons of toxin-exposed rats, reflecting a leaky intestinal epithelium that permits bacterial endotoxins to enter circulation. L. fermentum NCDC701 restored the expression of all three proteins, effectively re-sealing the barrier. This matters because a compromised gut lining is thought to be a gateway event in the gut-brain axis model of neurodegeneration: it allows lipopolysaccharides and other microbial products to trigger systemic inflammation, activate microglia in the brain, and promote amyloid aggregation. By reinforcing the barrier, the probiotic may be cutting the disease process off at one of its upstream sources.

Deep sequencing of the V3-V4 region of the 16S rRNA gene in faecal samples revealed how profoundly the toxin regimen disturbed the gut ecosystem, and how effectively the probiotic repaired it. Aluminium chloride and D-galactose lowered the Shannon diversity index and the number of observed operational taxonomic units, signatures of dysbiosis. The Firmicutes to Bacteroidetes ratio, 1.435 in healthy controls, fell to 1.03 in the disease model but rebounded to approximately 1.4 in all probiotic-treated groups. Beneficial genera such as Lactobacillus, Prevotella, Ruminococcus, and Oscillospira, the latter known to support IL-10-producing regulatory T cells, all recovered after probiotic administration, while pathogenic taxa including Spirochaetes, Porphyromonadaceae, Coprococcus, Clostridium, and Allobaculum receded. The disease model also showed elevated Proteobacteria, a phylum increasingly recognized as a microbial marker of dysbiosis and inflammation, which declined with treatment.

Metabolite analysis tied these microbial shifts to functional chemistry. Gas-liquid chromatography of faecal samples showed that the disease model was enriched in propionate, echoing previous reports of elevated propionic acid in the blood of Alzheimer’s patients, while butyrate and total short-chain fatty acids were depressed. Probiotic treatment restored the short-chain fatty acid profile, increasing butyrate, a molecule that fuels colonocytes, strengthens epithelial tight junctions, and can modulate anti-inflammatory pathways through G-protein-coupled receptors. Because short-chain fatty acids can enter the circulation, cross the blood-brain barrier, and influence vagal, endocrine, and immune signaling, their restoration provides a plausible mechanistic bridge between the microbial changes observed in the colon and the biochemical recovery documented in the brain.

The authors are candid about the study’s limitations. The biochemical and molecular analyses used small groups of three animals per condition, a constraint imposed by resource limitations during the COVID-19 pandemic, and no human clinical trials have yet tested the strain. Larger and more diverse cohorts will be needed to confirm the statistical robustness and generalizability of the results, and translational studies will be essential before any commercial application. Nevertheless, the convergence of histological, biochemical, transcriptional, microbiological, and metabolomic evidence around a single probiotic strain is unusual and compelling. If future work validates these findings in humans, L. fermentum NCDC701 could represent a new class of adjunct therapy for Alzheimer’s disease, one that works not by attacking plaques directly in the brain, but by rebuilding the microbial and barrier defenses of the gut, and letting the microbiota-gut-brain axis carry the benefit upward.

Subject of Research: Probiotic modulation of the gut-microbiota-brain axis in an aluminium chloride and D-galactose-induced rat model of Alzheimer's disease

Article Title: Ameliorative action of probiotics on the neurotoxicological effect of Aluminium chloride and D-galactose

Article References: Dasriya, V. L., Kumari, M., Ranveer, S., Behare, P., Vij, S., & Puniya, A. K. (2025). Ameliorative action of probiotics on the neurotoxicological effect of Aluminium chloride and D-galactose. Discover Toxicology, 2(1), Article 6. https://doi.org/10.1007/s44339-025-00022-0

Image Credits: AI Generated

DOI: 10.1007/s44339-025-00022-0

Keywords: probiotics, Limosilactobacillus fermentum, Alzheimer's disease, gut-brain axis, amyloid plaques, neuroinflammation, oxidative stress, GABA, short-chain fatty acids, gut microbiota, tight junction proteins, aluminium chloride